Stock Analiz

Keros Therapeutics, Inc. KROS

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$10.30Market cap $202M
Open the interactive analysis →

Keros Therapeutics, Inc. (KROS) is a healthcare company listed in the US with a market value of about $202M. In the twelve months to September 30, 2026 it had revenue of $41M and net income of -$62M, a net margin of -151.5%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -23%.

About Keros Therapeutics

Keros Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $10M in 2019 to $244M in 2025, growth of about 70.3% a year. It was profitable in 1 of the last 7 years in our data. Its share count rose by 50% over three years (dilution for shareholders). It spends 53% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.0
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-23.9%
Shareholder yield185.5%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)6769.4%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-26708.5%
ROIC (5-yr avg.)-23.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$41M$244M$4M$151000$0$20M$0$10M
Net income-$62M$87M-$187M-$153M-$105M-$59M-$45M-$12M
Free cash flow-$48M$106M-$163M-$127M-$71M-$63M-$37M-$16M
EPS (diluted)$-2.34$2.30$-5.00$-5.20$-4.15$-2.52$-2.93$-6.08
Net margin-151.5%35.7%-5277.6%-101300.0%—-292.3%—-123.4%
ROIC—20.0%-28.2%-49.0%-39.5%-18.2%-17.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $19.83, 93% above the current price; targets range from $16.00 to $25.00; the consensus rating is “Buy”; expected EPS is $-3.35 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Keros Therapeutics pay a dividend?

Not currently.

Is Keros Therapeutics a good stock to buy?

We do not give buy or sell advice. Keros Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.